Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73596374" target="_blank" >RIV/61989592:15110/19:73596374 - isvavai.cz</a>

Výsledek na webu

<a href="https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0508-1" target="_blank" >https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0508-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s40425-019-0508-1" target="_blank" >10.1186/s40425-019-0508-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Popis výsledku v původním jazyce

BackgroundWe evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1L-mn) or second-line (2L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy.MethodsIn a phase 1b expansion cohort, patients without (1L-mn) or with (2L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10mg/kg intravenously every 2weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety.ResultsOverall, 150 patients were enrolled (1L-mn, n=90; 2L, n=60) and median follow-up in the 1L-mn and 2L subgroups was 36.0 and 33.7months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1L-mn subgroup (n=2). In the 1L-mn and 2L subgroups, median duration of response was 21.4months (95% CI, 4.0-not estimable) and 3.5months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively.

Název v anglickém jazyce

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Popis výsledku anglicky

BackgroundWe evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1L-mn) or second-line (2L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy.MethodsIn a phase 1b expansion cohort, patients without (1L-mn) or with (2L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10mg/kg intravenously every 2weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety.ResultsOverall, 150 patients were enrolled (1L-mn, n=90; 2L, n=60) and median follow-up in the 1L-mn and 2L subgroups was 36.0 and 33.7months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1L-mn subgroup (n=2). In the 1L-mn and 2L subgroups, median duration of response was 21.4months (95% CI, 4.0-not estimable) and 3.5months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal for ImmunoTherapy of Cancer

ISSN

2051-1426

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

30

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

"nestránkováno"

Kód UT WoS článku

000458250800003

EID výsledku v databázi Scopus

—